Taking a lateral flow assay kit from a working strip to something that can be made repeatedly: why lateral flow assay manufacturing is a materials and tolerance problem rather than a chemistry problem, what nitrocellulose lot variation does to a validated line position, how conjugate drying and buffer choice decide shelf life, where reader based reading changes the claim you can make over a visual read, and what a manufacturing partner should demonstrate before a transfer
A lateral flow strip that works on the bench is a long way from a product. The membrane is a variable natural material, the conjugate is a colloid whose stability depends on the drying buffer, and the housing tolerances change the flow. Most scale up failures are traced to a material lot rather than to the assay design, and they surface late.
- the labelling clause behind research use only on a test kit
- 809.10(c)
- quality system regulation for medical devices, 21 CFR
- Part 820
- laboratory records, the clause behind a lot release record
- 211.194
The figures in this panel are regulation identifiers, named from the regulations themselves and linked below. They are not prices: BioBricks publishes verified prices for synthesis services only, and does not imply a manufacturing price index it has not measured.
- 4 vendor service pages verifiedevery figure matched verbatim to the vendor's page
- Quoted and dated, never estimatedlast verification pass 2026-08-24
- 1 service classes coveredeach with measured search demand behind it
From prototype to product
- Fix the membrane and qualify its lots. Capillary flow rate varies between membrane lots, and it moves line position, sensitivity and background. Choose one membrane, agree a flow rate specification with the supplier, and test each incoming lot before it enters production.
- Develop the conjugate for stability, not just for signal. Colloidal conjugates aggregate, and the drying buffer, sugars and blockers determine whether they survive storage. A conjugate optimised only for immediate signal will lose sensitivity within weeks.
- Treat every material as a controlled component. Sample pad, conjugate pad, absorbent pad, backing card, housing and desiccant each affect performance. Change control on all of them, with a stated part number and supplier, is what makes lots comparable.
- Decide visual against reader based interpretation. A visual read supports a qualitative claim; a reader supports a semi quantitative one and imposes its own validation, calibration and software obligations. Decide early because it changes the development and the labelling.
- Design the stability study before manufacturing. Real time and accelerated storage at defined conditions, with a defined test schedule and acceptance criteria, is what supports a shelf life claim. Retrospective stability is not a thing.
- Transfer with a demonstrated process, not a protocol. A manufacturing partner should run the process at their own scale, on their own equipment, with their own operators, and show three consistent lots before the transfer is accepted.
Nitrocellulose is a natural variable
Membrane capillary flow rate varies within a specification band, and assays developed at one end of that band behave differently at the other. Line position, incubation time and even apparent sensitivity move with it.
The practical control is to buy against a tighter flow specification than the standard one, test incoming lots, and design the assay with enough margin that ordinary lot variation does not cross an acceptance limit.
Where prototypes and products diverge
A prototype is made by a skilled person adjusting as they go. A product is made by a machine following fixed parameters. Anything in the prototype that depends on judgement has to be converted into a parameter with a tolerance before manufacture is possible.
Doing that conversion early, while the assay is still flexible, is far cheaper than discovering during a transfer that the assay only works when a particular person makes it.
Common questions
- Why does sensitivity change between batches?
- Membrane lot variation and conjugate stability, in that order. Both are managed by specification and incoming testing rather than by adjusting the assay, and a laboratory that re optimises each batch is not yet ready to manufacture.
- How is shelf life established?
- By real time storage at the labelled condition, supported by accelerated data, against defined acceptance criteria set before the study. Accelerated data alone supports a provisional claim at best.
- Does a reader change the regulatory position?
- It changes what can be claimed and adds software and calibration obligations. A semi quantitative result carries more expectation about precision and traceability than a visual yes or no.
- What should a manufacturing partner demonstrate?
- Three consecutive conforming lots at scale on their equipment, incoming material control including membrane flow testing, a documented process with defined critical parameters, and their own stability data on lots they made.
Get a shortlist for your project
Browse by service class
Sources
Cite or embed this figure
The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.
Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/lateral-flow-assay-kit/.